Eli Lilly And Company (LLY)
NYSE:LLY
Want to see LLY full AI Analyst Report?
LLY Stock Chart & Stats
$927.03
$13.01(1.27%)
At close: 4:00 PM EST
$927.03
$13.01(1.27%)
Day’s Range― - ―
52-Week Range$623.78 - $1,133.95
Previous Close$1,036.53
Volume3.30M
Average Volume (3M)2.74M
Market Cap
$911.54B
Enterprise Value$952.61B
Total Cash (Recent Filing)$5.28B
Total Debt (Recent Filing)$43.37B
Price to Earnings (P/E)27.8
Beta0.69
Next Earnings
Aug 04, 2026EPS Estimate
8.67Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)28.20
Shares Outstanding941,741,400
10 Day Avg. Volume2,553,212
30 Day Avg. Volume2,742,315
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue13.18
Enterprise Value/Gross Profit15.79
Enterprise Value/Ebitda28.75
Forecast
1Y Price Target
$1,262.85Price Target Upside36.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)35.93
Revenue Forecast (FY)$83.77B
Bulls Say, Bears Say
Bulls Say
M&A And Pipeline DiversificationPipeline diversification via acquisition: Purchase of the neuroscience asset adds cleminorexton for underserved sleep disorders, broadening the pipeline beyond metabolic franchises and reducing dependence on existing products' sales.
Manufacturing And FormulationManufacturing and formulation: Approval of a tablet formulation for Foundayo, supported by bioequivalence to the trial capsules, lowers active ingredient use and enables simpler, more scalable production that should improve supply economics.
Regulatory/post‑marketingRegulatory: Post‑marketing study requirements for Foundayo are manageable and do not restrict promotion or impose strict risk‑management constraints, preserving commercialization flexibility and supporting market adoption.
Bears Say
Label And Prescribing ConstraintsLabel and prescribing constraints: The drug label warns about interactions with certain metabolic and cholesterol medications, which could complicate treatment use for patients on those therapies and reduce the addressable patient population.
Market Expectations And ValuationMarket expectations and valuation: Launch expectations for Foundayo appear largely reflected in the stock, limiting immediate upside from approval and placing greater emphasis on execution against consensus forecasts.
Pricing And ReimbursementPricing and reimbursement: Continued pricing pressure in the cash‑pay channel may moderate revenue growth for incretin medicines despite strong prescription momentum, creating downside risk to sales forecasts.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly And Company’s price range in the past 12 months?
Eli Lilly And Company lowest stock price was $623.78 and its highest was $1133.95 in the past 12 months.
What is Eli Lilly And Company’s market cap?
Eli Lilly And Company’s market cap is $911.54B.
When is Eli Lilly And Company’s upcoming earnings report date?
Eli Lilly And Company’s upcoming earnings report date is Aug 04, 2026 which is in 91 days.
How were Eli Lilly And Company’s earnings last quarter?
Eli Lilly And Company released its earnings results on Apr 30, 2026. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.972 by $1.578.
Is Eli Lilly And Company overvalued?
According to Wall Street analysts Eli Lilly And Company’s price is currently Undervalued.
Does Eli Lilly And Company pay dividends?
Eli Lilly And Company pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 0.58%. See more information on Eli Lilly And Company dividends here
What is Eli Lilly And Company’s EPS estimate?
Eli Lilly And Company’s EPS estimate is 8.67.
How many shares outstanding does Eli Lilly And Company have?
Eli Lilly And Company has 941,741,400 shares outstanding.
What happened to Eli Lilly And Company’s price movement after its last earnings report?
Eli Lilly And Company reported an EPS of $8.55 in its last earnings report, beating expectations of $6.972. Following the earnings report the stock price went up 9.797%.
Which hedge fund is a major shareholder of Eli Lilly And Company?
Currently, no hedge funds are holding shares in LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,262.85 (36.23% Upside)
$1,262.85 (36.23% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Bullish
Bullish news 79%
Bearish news 16%
Bearish news 16%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.18%
12-Months-Change
Fundamentals
Return on Equity
97.85%
Trailing 12-Months
Asset Growth
30.41%
Trailing 12-Months
Company Description
Eli Lilly And Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY Company Deck
LLY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: exceptional revenue and earnings growth, raised guidance, robust international momentum for incretins, successful clinical readouts (including cardiovascular safety for Foundayo), an ambitious pipeline with 42 active Phase III programs, and multiple strategic acquisitions to broaden capabilities. The principal concerns are meaningful pricing pressure (expected low-to-mid-teens headwind), increased marketing and R&D spend, access variability (Medicaid and payer coverage), early-stage uncertainty around Foundayo's ultimate contribution, and competitive/generic dynamics in some markets. On balance, the highlights materially outweigh the lowlights.View all LLY earnings summariesLLY Revenue Breakdown
35.23% Mounjaro
20.78% Zepbound
8.78% Verzenio
35.21% Other products
LLY Stock 12 Month Forecast
Average Price Target
$1,262.85
▲(36.23% Upside)
Technical Analysis
Ownership Overview
9.88% Insiders
22.76% Mutual Funds
13.02% Other Institutional Investors
35.75% Public Companies and Individual Investors